Singaporean biotech startup Curiox receives US$15M investment, planning Korean IPO
Curiox Biosystems, a bio-instrumentation startup based in Singapore, announced that it has received US$15 million in its Series B funding round from Korean biotech investors, DealStreetAsia reported.
The investors in the Series B funding round include KB Investment, Dayli Partners, Quad Investment Management, IMM Investment, SV Investment Partners, and HB Investment.
The company notes that the fresh funding will be used for global commercialisation activities and to scale up. “Our new funding will help us expand our global reach to the flow cytometry community and other cell-based assay developers,” said CEO Namyong Kim.
Curiox also revealed plans to pursue an initial public offering on the Korean stock exchange, KOSDAQ, in the next 36 months, given its now-backer is from the country.
In a statement, Zig Ventures said that the Korean biotech investors who are attracted to Curiox’s bio-instrumentation solutions developed for cell analysis and therapy in the pharma and biotech industries.
Curiox is a spinoff bio-instrumentation company of the Agency for Science, Technology, and Research (A*STAR) in Singapore. Curiox is led by Chief Executive Officer Dr. Namyong Kim and provides products like the Laminar Wash HT1000 System and two new systems, the Laminar Wash AUTO1000 and Laminar Wash MINI.